Company Name, Ticker, Customers, else..

• Gross Margin

• EBITDA Margin

• Operating Margin

• Pre-Tax Margin

• Effective Tax Rate

• Free Cash Flow Margin

• Cash Flow Margin

Valuation Comparisons

Management Effectiveness

Financial Strength

Dividend Comparisons

Pfizer Inc (NYSE: PFE)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Pfizer Inc Profitability Comparisons

Select each Category to receive further Information

Select the Comparisons :

Profitability ▼

Select the Ratio:

None▼

Profitability ▼

None▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PFE Profitability Ratio	Company	Industry	Sector	S&P 500
Gross Profit Margin (Q2 MRQ)	72.78 %	70.86 %	67.38 %	46.15 %
Gross Margin (Q2 TTM)	73.18 %	71.39 %	67.8 %	46.36 %
Gross Profit Margin 5 Yr. Avg.	66.29 %	67.81 %	65.55 %	48.95 %
EBITDA Margin (Q2 MRQ)	6.45 %	21.18 %	18.45 %	20.46 %
EBITDA Margin (Q2 TTM)	16.94 %	25.13 %	20.78 %	20.1 %
EBITDA Margin 5 Yr. Avg.	26.94 %	47.09 %	31.38 %	23.39 %
Operating Margin (Q2 MRQ)	0 %	17.04 %	16.52 %	16.05 %
Operating Margin (Q2 TTM)	19.62 %	20.45 %	17.83 %	16.34 %
Operating Margin 5 Yr. Avg.	21.08 %	15.37 %	14.33 %	19.26 %
Pre-Tax Profit Margin (Q2 MRQ)	-4.34 %	13.42 %	10.72 %	13.96 %
Pre-Tax Profit Margin (Q2 TTM)	6.61 %	16.68 %	12.68 %	13.09 %
Pre-Tax Profit Margin 5 Yr. Avg.	18.19 %	12.98 %	10.37 %	13.52 %
Net Margin (Q2 MRQ)	-1.58 %	9.91 %	8.02 %	11.42 %
Net Margin (Q2 TTM)	6.86 %	13.16 %	9.86 %	10.76 %
Net Margin 5 Yr. Avg.	17.45 %	5.79 %	6.08 %	10.8 %

Business Segment			Profit Margin

Other Business Activities			-
Biopharma			-
U S			-
International Developed Markets			-
International Emerging Markets			-
Biopharma U S Commercial Division			-
Biopharma International Commercial Division			-
Pfizer CentreOne			-
Total Alliance revenues			-
Primary Care Biopharma			-
Primary Care Eliquis Biopharma			-
Primary Care Paxlovid Biopharma			-
Primary Care Prevnar Family Biopharma			-
Primary Care Comirnaty Biopharma			-
Primary Care Nurtec ODT Vydura Biopharma			-
Primary Care Abrysvo Biopharma			-
Primary Care FSME-IMMUN TicoVac Biopharma			-
Primary Care All other Primary Care Biopharma			-
Specialty Care Biopharma			-
Specialty Care Vyndaqel family Biopharma			-
Specialty Care Xeljanz Biopharma			-
Specialty Care Enbrel Outside the U S and Canada Biopharma			-
Specialty Care Octagam Biopharma			-
Specialty Care Genotropin Biopharma			-
Specialty Care Cibinqo Biopharma			-
Specialty Care All other Specialty Care Biopharma			-
Oncology Biopharma			-
Oncology Ibrance Biopharma			-
Oncology Xtandi Biopharma			-
Oncology Padcev Biopharma			-
Oncology Adcetris Biopharma			-
Oncology Inlyta Biopharma			-
Oncology Lorbrena Biopharma			-
Oncology Bosulif Biopharma			-
Oncology Braftovi Mektovi Biopharma			-
Oncology Tukysa Biopharma			-
Oncology Tivdak Biopharma			-
Oncology Talzenna Biopharma			-
Oncology All other Oncology Biopharma			-
Comirnaty			-
Paxlovid			-
Government and Government Sponsored Paxlovid and Comirnaty			-
Royalty			-
Specialty Care Zavicefta Outside the U S and Canada Biopharma			-
Oncology Orgovyx Biopharma			-
Oncology Elrexfio Biopharma			-
Biopharma Global Hospital and Biosimilars Division			-
Hospital and Biosimilars Biopharma			-
Hospital and Biosimilars Oncology Biosimilars Biopharma			-
Hospital and Biosimilars Sulperazon Outside the U S and Canada Biopharma			-
Hospital and Biosimilars Inflectra Biopharma			-
Hospital and Biosimilars Zithromax Biopharma			-
Hospital and Biosimilars All Other Hospital and Biosimilars Biopharma			-

Company's Cashflow Profitability & Other

Profitability Ratios	Company	Industry	Sector	S&P 500
Free Cash Flow Margin (Q2 MRQ)	2.01 %	-0.01 %	0.22 %	1.39 %
Free Cash Flow Margin (Q2 TTM)	17.25 %	17.47 %	13.83 %	9.08 %
Free Cash Flow Margin 5 Yr. Avg.	-	19.28 %	14.86 %	15.58 %
Net Cash Flow Margin (Q2 MRQ)	0 %	0.02 %	-0.02 %	0.13 %
Net Cash Flow Margin (Q2 TTM)	0.1 %	-0.36 %	0.15 %	1.85 %
Net Cash Flow Margin 5 Yr. Avg.	-	4.38 %	3.16 %	6.44 %
Effective Tax Rate (Q2 MRQ)	-	25.94 %	25.04 %	18.8 %
Effective Tax Rate (Q2 TTM)	-3.9 %	21.36 %	23 %	19.44 %
Effective Tax Rate 5 Yr. Avg.	-18.41 %	15.08 %	20.51 %	19.76 %

Note
To view Detail Information & Trends click on Individual Category. Example: Y / Y Revenue Change (MRQ) or To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table. Example: Industry Sector S&P 500 For explanation of terms visit: Glossary

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.